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Abstract
Background: Antidepressant drugs (ADs) have been shown to activate BDNF (brain-derived neurotrophic factor) receptor
TrkB in the rodent brain but the mechanism underlying this phenomenon remains unclear. ADs act as monoamine reuptake
inhibitors and after prolonged treatments regulate brain bdnf mRNA levels indicating that monoamine-BDNF signaling
regulate AD-induced TrkB activation in vivo. However, recent findings demonstrate that Trk receptors can be transactivated
independently of their neurotrophin ligands.
Methodology: In this study we examined the role of BDNF, TrkB kinase activity and monoamine reuptake in the AD-induced
TrkB activation in vivo and in vitro by employing several transgenic mouse models, cultured neurons and TrkB-expressing
cell lines.
Principal Findings: Using a chemical-genetic TrkBF616A mutant and TrkB overexpressing mice, we demonstrate that ADs
specifically activate both the maturely and immaturely glycosylated forms of TrkB receptors in the brain in a TrkB kinase
dependent manner. However, the tricyclic AD imipramine readily induced the phosphorylation of TrkB receptors in
conditional bdnf2/2 knock-out mice (132.468.5% of control; P = 0.01), indicating that BDNF is not required for the TrkB
activation. Moreover, using serotonin transporter (SERT) deficient mice and chemical lesions of monoaminergic neurons we
show that neither a functional SERT nor monoamines are required for the TrkB phosphorylation response induced by the
serotonin selective reuptake inhibitors fluoxetine or citalopram, or norepinephrine selective reuptake inhibitor reboxetine.
However, neither ADs nor monoamine transmitters activated TrkB in cultured neurons or cell lines expressing TrkB
receptors, arguing that ADs do not directly bind to TrkB.
Conclusions: The present findings suggest that ADs transactivate brain TrkB receptors independently of BDNF and
monoamine reuptake blockade and emphasize the need of an intact tissue context for the ability of ADs to induce TrkB
activity in brain.
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Introduction
TrkB (tropomyosin-related kinase B) neurotrophin receptor
transduces intracellular signaling events that are critical for neuronal
differentiation, survival and plasticity throughout life [1–5]. Brain-
derived neurotrophic factor (BDNF) is the main endogenous ligand
for TrkB [3], but recent evidence demonstrates that TrkB can also be
transactivated independently of BDNF or other neurotrophins
through neuromodulator receptors [6,7] and small molecules [8,9].
Abnormal TrkB receptor signaling has been linked to a number
of central nervous system (CNS) diseases such as mood and
memory disorders and addiction [10–12]. Accumulating evidence
suggests that antidepressant drugs (AD) that regulate the brain
levels of monoamine neurotransmitters serotonin and norepineph-
rine, act at least partially by activating TrkB receptor signaling in
brain [13,14]. ADs have been shown to rapidly induce the
phosphorylation and activation of TrkB receptors in the rodent
cortex and hippocampus [13,15]. When administered chronically,
ADs also increase BDNF mRNA and protein levels and TrkB
phosphorylation in brain [13,15,16]. Furthermore, animal studies
suggest that many of the behavioral and functional actions of ADs
are attenuated in mice with reduced BDNF signaling in brain
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[13,17]. Levels of BDNF are reduced in the brain and serum of
depressed patients and the levels are returned back to normal
range upon a successful treatment with ADs [18,19].
In this study we have examined several potential molecular
mechanisms of AD-induced TrkB activation in vitro and in vivo. We
show that both mature and immature forms of TrkB can be
specifically tyrosine phosphorylated by ADs, but neither the
endogenous ligand BDNF, nor the serotonin transporter (SERT),
the principal target of many ADs, is required for this effect.
However, the observation that ADs or serotonin (5-HT) or
norepinephrine (NE) do not activate TrkB phosphorylation in vitro
argues that ADs do not directly bind to TrkB receptors.
Results
Antidepressant drugs specifically activate TrkB receptors
in mouse brain
Previous studies suggest that BDNF-TrkB signaling is critical
for the behavioral effects of ADs [13,17] and that ADs activate
Trk receptors in vivo. We have previously shown that several
independent antibodies raised against phosphorylated tyrosines
Y705/706 or Y816 within the intracellular domain of TrkB all
show increased phospho-TrkB levels after acute and chronic
AD treatment [13,15], while no increase is detected with
antibodies against the shc binding site at pY515. Furthermore,
immunoprecipitation with Trk specific antibodies and probing
with pTyr-antibodies also reveals increased TrkB phosphoryla-
tion [13,15,20]. However, since phospho-Trk antibodies are not
completely specific for TrkB, we investigated whether the
protein phosphorylated by the acute AD treatment is indeed
TrkB. We pretreated TrkBF616A knock-in mice [21] with
NaPP1, a chemical that specifically inhibits TrkB kinase
activity in these mutant mice, and then injected the mice
acutely with imipramine. Whereas imipramine readily induced
rapid activation of brain TrkB in vehicle-treated TrkBF616A
knock-in mice, NaPP1 treatment abolished this effect
(Figure 1A–B). Furthermore, when we treated transgenic mice
over-expressing flag-tagged TrkB receptors in adult neurons
(TrkB.TK+) [22,23] with imipramine, we observed enhanced
phosphorylation of the TrkB specific band when compared to
wild-type mice (data not shown). Importantly, when TrkB
receptors were immunoprecipitated with a Flag antibody from
TrkB.TK+ mouse brain homogenates, phospho-TrkB signal
was more intense in samples of imipramine treated animals
(Figure 1C). Collectively, these data demonstrate that
imipramine specifically induce phosphorylation of TrkB recep-
tors in mouse brain.
The immaturely glycosylated form of TrkB is
phosphorylated by antidepressants
As we have previously shown [13], an additional low-molecular
weight (LMW) phospho-Trk –immunoreactive protein (about
105 kDa) is robustly phosphorylated in the rodent brain after
single or repeated AD treatment (Figure 2A). This phosphor-
ylated protein is detected by the same antibodies that demon-
strate the phosphorylation of TrkB after AD treatment (Figure
S1A–B) and has been detected following TrkB immunoprecip-
itation and hybridization to pTyr antibodies [13,20]. AD-induced
phosphorylation of both the full-length TrkB and the 105 kDa
protein is also readily detected in different brain regions including
striatum, midbrain and cerebellum (data not shown), but, similar
to full-length TrkB, its phosphorylation is diluted in whole brain
homogenate (Figure S1C). However, this band cannot be
reliably detected by antibodies against the non-phosphorylated
intracellular domain of Trk receptors (Figure 2A).
This lower molecular weight protein might represent an
immaturely glycosylated form of catalytic TrkB [24], as TrkB
transactivation has been shown to coincide with accumulation of
intracellular immaturely glycosylated TrkB species [6,7,25]. We
therefore further examined the glycosylation structure of this
protein using endoglycosidase-H (Endo-H) that cleaves immature
high-mannose rich N-glycans out of proteins. Endo-H digestion
produced a slight reduction in the molecule weight of the mature
full-length TrkB, suggesting that the mature TrkB still contains
immature-type glycan residues (Figure 2B), as also observed
before for TrkA [26]. Importantly, Endo-H treatment strongly
reduced the molecular weight of 105 kDa protein (Figure 2B),
suggesting that essentially all the glycan residues in this protein
represent immature high-mannose rich N-glycans. These data are
consistent with the interpretation that the 105 kDa protein
represents an immaturely glycosylated and intracellularly located
species of TrkB. This interpretation is further supported by the
observations that the basal phosphorylation levels of this
phosphoprotein are increased in the brains of TrkB over-
expressing mice (Figure 2C) and that the activation of this
band is lost after 1NaPP1 treatment in the TrkBF616A mice
(Figure 1B).
Antidepressant-induced TrkB activation does not require
BDNF
Previous studies have shown that acute AD treatment does not
influence BDNF mRNA or protein levels [13,16]. Since it has
recently been suggested that pro and mature forms of BDNF
might have different capacities to activate TrkB [27], we
investigated the effects of acute antidepressant treatment on
proBDNF cleavage in brain. However, we were not able to detect
any proBDNF signal in wild-type mouse brain, even if the
antibody readily detected the recombinant proBDNF control
protein (Figure S2A). Nevertheless, acute fluoxetine treatment,
with a dose and time point (30 mg/kg; 1 hour) which induced
TrkB phosphorylation in mouse hippocampus [13,15], failed to
produce any significant changes in the levels of the mature BDNF
(mBDNF) in mouse brain as detected with western blotting
(Figure S2A). Furthermore, fluoxetine did not influence the
activity of tissue plasminogen activator (tPA), the major regulator
of pro-BDNF cleavage into mBDNF (Figure S2B). These data
suggest that ADs do acutely not influence BDNF levels or
processing in brain.
Although BDNF is the main ligand of TrkB, recent evidence
suggests that TrkB can also be activated independently of BDNF
in neurons [6,8,9]. We therefore used conditional BDNF mutant
mice (BDNF2L/2LCk-cre) lacking BDNF in forebrain regions [28] to
investigate whether BDNF is required for the AD-induced TrkB
activation in brain in vivo. Imipramine readily induced tyrosine
phosphorylation of both the mature and the immature glycosy-
lated forms of TrkB in the hippocampus of conditional BDNF2L/
2LCk-cre mice (Figure 3). Similarly, imipramine produced an
increase in brain TrkB phosphorylation in heterozygous bdnf+/2
null mice and wild-type mice (data not shown). These data
demonstrate that ADs activate TrkB receptors in the mouse brain
in a manner independent of BDNF.
Adenosine has been shown to transactivate TrkB receptors
via adenosine-2A signaling in the absence of BDNF in vitro and in
vivo [6,29] and to enhance TrkB signaling [30]. Furthermore,
some ADs have been shown to acutely increase the extracellular
levels of adenosine by reducing adenosine reuptake [31]. We
therefore tested whether prior pharmacological inhibition of
Antidepressants Transactivate TrkB Receptors
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adenosine A2A receptors with ZM241385 might block the acute
effects of ADs on TrkB phosphorylation. We found that,
imipramine increased the phosphorylation of TrkB receptors
similarly in mice pretreated with saline or active dose [32,33] of
ZM241385 (Figure S3), suggesting that A2A receptors were not
involved.
Amitriptyline, but not imipramine, was recently shown to
directly bind and transactivate TrkB receptors in vitro [9]. We
therefore tested whether amitriptyline, imipramine or other
selected drugs could directly phosphorylate TrkB receptors in
two different cell models: fibroblast expressing catalytic TrkB
receptors and E18 rat primary hippocampal and cortical neuronal
cultures. In both of these cells, BDNF produces a robust
phosphorylation of TrkB. However, exposure to tested ADs,
including amitriptyline, or other tested drugs did not regulate
TrkB phosphorylation status in these cultures (Figures 4A, S4).
We further tested whether ADs might potentiate the pTrkB
response induced by a small dose of BDNF or whether
depolarization of neurons might render them sensitive to ADs in
vitro. Imipramine did not facilitate BDNF-induced TrkB phos-
phorylation in vitro (Figure 4B), which is in line with the findings
in BDNF deficient mice. Similarly, even when ADs were coupled
with depolarization stimuli (50 mM K+), no significant changes in
TrkB phosphorylation were seen (Figure 4C).
TrkB activation by antidepressant drugs is not mediated
by the serotonin transporter or monoamine transmitters
Essentially all clinically used antidepressant drugs acutely
increase the extracellular levels of NE and/or 5-HT in brain
and we therefore investigated the role of these monoamines in the
AD-induced TrkB transactivation in vivo and in vitro. First we
examined the effect of fluoxetine, a prototypic SERT selective
reuptake inhibitor (SSRI), on TrkB receptor phosphorylation in
SERT knockout mice (sert2/2). A 6–10 fold up-regulation of
extracellular 5-HT levels in sert2/2 mice [34] did not regulate
basal TrkB phosphorylation levels in hippocampus when com-
pared to the wild-type controls (89.43%66.43% of wild-type,
P= 0.19, Student t-test). Importantly, fluoxetine readily induced
the phosphorylation of both the mature and immature forms of
TrkB in the brains of sert2/2 mice in a manner indistinguishable of
the wild-type mice (Figure 5A), indicating that SERT is
dispensable to the fluoxetine-induced TrkB autophosphorylation.
Because the selectivity of the ADs against different transporters
is only relative, we performed chemical lesion experiments to
reduce brain 5-HT (by pCPA treatment) and NE levels (by DSP4)
and used selective 5-HT and NE transporter blockers citalopram
and reboxetine, respectively. As noted before [15], citalopram and
reboxetine produced a non-significant trend of increase in TrkB
autophosphorylation levels in pCPA and DSP4 treated mice,
Figure 1. Imipramine specifically activates TrkB receptors in the mouse brain. A) The ability of imipramine (30 mg/kg, i.p., 30 min; n = 6/
group) to induce rapid TrkB phosphorylation in the hippocampus and medial prefrontal cortex of TrkBF616A mutant mice is abolished with 1NaPP1
pretreatment (25 mM for 1-week in drinking water+83 ng/g co-injection with imipramine). B) A representative blot showing TrkB kinase dependent
action of imipramine-induced phosphorylation of TrkB (Y816) and the ,105 kDa protein. C) A representative blot showing imipramine-induced TrkB
phosphorylation in flag-precipitated pool of protein from the brains of mice over-expressing flag-tagged catalytic TrkB receptors. Data is presented as
percentage of control/saline 6 standard error of mean (SEM). *,0.05, **,0.01; two-way ANOVA with Newmann-Keuls post hoc test.
doi:10.1371/journal.pone.0020567.g001
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respectively (Figure 5B). However, citalopram and reboxetine
induced a strong and highly significant increase in the phosphor-
ylation of the immaturely glycosylated form of TrkB in pCPA and
DSP4 treated mice, respectively (Figure 5B). These observations
suggest that even when brain 5-HT and NE levels are very low,
ADs can activate at least the immaturely glycosylated form of
TrkB.
Finally, we tested whether NE or 5-HT would directly regulate
TrkB phosphorylation in cultured primary neurons. Under
conditions where BDNF robustly induced TrkB phosphorylation,
incubation with different concentrations of NE or 5-HT did not
regulate TrkB phosphorylation levels in primary neuronal cultures
(Figure 5C). Collectively, these data suggest that TrkB receptor is
activated in mouse brain by ADs independent of monoamine
reuptake inhibition.
Discussion
Emerging evidence suggests a key role of the BDNF-TrkB
signaling in the regulation of many of the molecular and
behavioral actions of ADs. ADs acutely and chronically increase
TrkB signaling [13,15]. Moreover, chronic, but not acute, AD
treatment increases BDNF synthesis in the rodent brain [16,35].
BDNF injection and TrkB activation produce AD-like responses in
rodents [36–38], while mice deficient of BDNF or with inhibited
TrkB signaling do not respond to ADs in the forced swim test
[13,17], the classical paradigm for AD effectiveness. These data
suggest that, at least in rodents, activation of TrkB receptors
induced by BDNF is essential for the antidepressant effect.
However, we show here that rapid activation of TrkB in response
to AD administration in vivo does not require BDNF release. This
finding does not rule out the role of BDNF in regulating TrkB
activation following chronic AD treatment. Since acute AD
treatment increases phosphorylation of CREB, a critical upstream
regulator of BDNF synthesis in a TrkB dependent manner [13], it
is tempting to speculate that this ligand-independent TrkB
activation is contributing the AD-induced BDNF synthesis in
brain [39] which further leads to BDNF-dependent TrkB
phosphorylation after prolonged AD administration.
Fluoxetine and SSRIs act primarily by blocking 5-HT reuptake
in brain and BDNF, through TrkB, is a crucial regulator of
serotonergic innervation [40,41]. However, neither the SERT nor
the monoamines 5-HT or NE appear to be required for the
activation or TrkB by the ADs. We have previously shown that
representatives of all the different chemical classes of ADs similarly
increase TrkB phosphorylation in mouse brain, suggesting that the
monoamine independent TrkB activation may be a common
feature for all the ADs. Accumulating evidence has shown that
ADs, including fluoxetine and tricyclic ADs, have several
additional targets in cells such as neurotransmitter receptors
[42,43], ion channels [44], Sigma-1 receptors [45] and adenosine
Figure 2. Antidepressant drugs activate the immaturely
glycosylated form of TrkB. A) Acute imipramine treatment induces
the phosphorylation (Y816) of full-length and low-molecular weight
(LMW; ,105 kDa) TrkB receptors in mouse brain. n = 6/group. B)
Antidepressant-induced ,105 kDa protein is sensitive to Endo-H
digestion. A representative blot of triplicate data. C) Total TrkB,
phosphorylated TrkB (Y816) and phosphorylated ,105 kDa protein
levels are increased in the brains of mice over-expressing catalytic TrkB
receptors. n = 5/group. Data is presented as percentage of control 6
standard error of mean (SEM). *,0.05, ***0.005; unpaired two-tailed t-
test.
doi:10.1371/journal.pone.0020567.g002
Figure 3. Role of BDNF in antidepressant-induced rapid TrkB
activation in brain. Imipramine (30 mg/kg, 30 min, i.p.) readily
increases the phosphorylation of TrkB receptors (Y816) in forebrain
specific BDNF2/2 knock-out mice (BDNF2L/2LCk-cre) n = 4/group. Data is
presented as percentage of control 6 standard error of mean (SEM).
*,0.05; unpaired two-tailed t-test.
doi:10.1371/journal.pone.0020567.g003
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reuptake proteins [31] that could potentially be involved in
regulating TrkB signaling. Since adenosine-A2A receptor signaling
has been linked to TrkB signaling [30], we tested the role of this
receptor in AD-induced TrkB response by pharmacologically
blocking this receptor before imipramine challenge. However, no
change was observed compared to control treatment indicating
that adenosine is not a critical regulator of TrkB activation in
response to AD treatments.
While all the different ADs readily induce TrkB autophospho-
rylation in rodent brain [13,15], neither these compounds nor
monoamines do, in our hands, induce TrkB phosphorylation
in vitro in cultured cortical or hippocampal neurons, or in cell lines
stably expressing TrkB receptors. A recent study reported that
amitriptyline, but not imipramine, binds to TrkB receptors,
induces their dimerization and autophosphorylation in cultured
hippocampal neurons [9]. The reasons that underlie the
discrepancy between that study and our results with amitriptyline
are currently unclear, however, they may be related to the culture
conditions used. The lack of activation of TrkB by ADs in cultured
neurons is in line with our recent unpublished observations
showing that the ability of ADs to activate TrkB in vivo is
developmentally regulated: ADs do not activate TrkB in
Figure 4. Antidepressant drugs amitriptyline and imipramine do not regulate TrkB phosphorylation in primary neurons. A) Whereas
BDNF (20 ng/ml; 15 min) robustly increases the phosphorylation of TrkB (Y816) in E18 rat cortical and hippocampal neurons (14 DIV), amitriptyline
(left & middle; 0.5 mM, 5 mM; 15 min) and imipramine (0.5 mM, 5 mM; 50 mM; 15 min) produces no change on TrkB phosphorylation. Representative
blot of triplicate data. B) Imipramine pre-treatment (4, 12, 40 mM; 15 min) did not facilitate BDNF-induced (5 ng/ml; 15 min) TrkB phosphorylation in
E18 rat cortical neurons as measured with phospho-TrkB ELISA. n = 4/group. C) Imipramine pre-treatment (4, 12, 40 mM; 15 min) did not regulate TrkB
phosphorylation in its own or in combination with depolarization stimuli (50 mM KCl; 15 min) as measured with phospho-TrkB ELISA. n = 4/group.
Data is presented as percentage of control 6 standard error of mean (SEM). *,0.05; one-way ANOVA with Newmann-Keuls post hoc test.
doi:10.1371/journal.pone.0020567.g004
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embryonic or early postnatal mice, but the ability of these
compounds to induce pTrkB response appears only around
postnatal day 15 (P15) (ADL, TR and EC, submitted). Taken
together, these data suggests us that ADs do not directly bind to
TrkB, but, instead, emphasize the importance of developmental
processes and intact tissue context in the ability of small molecule
weight drugs such as ADs to activate TrkB autophosphorylation
in vivo.
Materials and Methods
Animal experiments - Wild-type (C57/BL6), TrkB.TK+ mutant
[22,23], trkBF616A knock-in [21], BDNF2L/2LCk-cre [28] and sert2/2
knock-out mice [46,47] were used in animal experiments. Mice
were group-housed in standard laboratory conditions and food
and water were freely available. All the experiments were carried
out according to the guidelines of the Society for Neuroscience and
were specifically approved by the University of Helsinki Commit-
tee on Animal Experiments (permit: HY 137-05) or the County
Administrative Board of Southern Finland (Permit: ESLH-2007-
09085/Ym-23). Unless otherwise stated all the tested chemicals
used in these studies are purchased from Sigma-Aldrich.
In vivo drug treatments - Mice received a single i.p. injection of
tested chemical or saline and after indicated time the mice were
killed with CO2 and brain area of interest dissected on a cooled
plastic dish. Next the samples were lyzed in NP++ buffer (137 mM
NaCl, 20 mM Tris, 1% NP-40, 10% glycerol, 48 mM NaF, H2O,
26 Complete inhibitor mix (Roche) and 2 mM Na3VO4),
incubated on ice (.30 min) and centrifugated (+4uC for 15 min,
16100 g). The supernatant was processed further as described
below. The following chemicals were used: fluoxetine-HCl (Orion
Pharma), citalopram-HBr (GlaxoSmithKline; GSK), imipramine-
HCl, moclobemide (kind gift from F Hoffmann-La Roche Ltd),
clomipramine-HCl, amitriptyline-HCl, reboxetine (GSK). Rebox-
etine and moclobemide were first stock-dissolved in DMSO,
citalopram in ethanol, others directly in saline. In order to inhibit
TrkB kinase activity prior drug administration in TrkBF616A
knock-in mice, mice were pre-treated with 25 mM of 1NaPP1
(kindly provided by Prof. Jari Yli-Kauhaluoma, Univ. Helsinki,
Finland) for 7 days (in drinking solution) and further co-injected
i.p. (83 ng/g) with imipramine or vehicle. ZM241358 was injected
i.p. to block adenosine A2A receptors 30 min prior imipramine
treatment [33]. Brain NE and 5-HT levels were depleted using
DSP-4 (brain NE levels ,20% of control; P,0.01, t-test) and
pCPA (brain 5-HT levels ,15% of control; P,0.005, t-test)
injections as described previously [15].
Tissue plasminogen activator (tPA) SDS-PAGE zymography -
For tPA activity assay, freshly dissected brain samples were
homogenized into buffer consisting of 0.1 M Tris-HCl (pH 8.0),
2.5% Triton-X-100, 10 mM leupeptin, 10 mg/ml aprotinin, 1 mM
phenylmethanesulfonylfluoride (PMSF). Samples and controls
(human recombinant tPA) were loaded under non-reducing
conditions in SDS-PAGE containing6human plasminogen (Sig-
ma-Aldrich) and pre-heated non-fat dry milk at low current (,15–
20 mA) over night (O/N) at cold bath. Next the gels were rinsed
thoroughly with 2.5% Triton X-100 to remove SDS and allow
proteins to renaturate. Next the gels were rinsed thoroughly with
10 mM CaCl2 50 mM Tris-HCl (pH 7.6) to remove Triton X-100
and the caseinolysis was allowed to occur by incubating the gels at
+37uC for 16–24 h in the same solution. Caseinolytic areas were
shown as translucent areas when the gels were stained with
Coomassie Brilliant Blue.
In vitro experiments - For the primary neuronal cultures,
hippocampi or cortex was dissected from E18 rat embryos and the
tissue dissociated in a papain solution (in mg: 10 DL-Cystein-HCl,
10 bovine serum albumin (BSA), 250 glucose, ad 50 ml PBS;
Figure 5. Monoamines and monoamine reuptake in TrkB activation in vitro and in vivo. A) Serotonin selective reuptake inhibitor fluoxetine
produced essentially similar changes on hippocampal TrkB phosphorylation in the brains of wild-type and serotonin transporter KO mice, sert2/2.
n = 3–5/group. B) Whereas the ability of serotonergic antidepressant citalopram (20 mg/kg, i.p., 60 min) and norepinephrinergic antidepressant
reboxetine (20 mg/kg, i.p., 30 min) to induce full-length TrkB receptor phosphorylation (Y816) in mice depleted of serotonin (with pCPA) or
norepinephrine (with DSP-4) are reduced, ,105 kDa protein is heavily phosphorylated by both drugs in the hippocampi of these mice.
Representative blots. n = 6–7/group. C) Norepinephrine (NE; 10 nM-10 mM; 15 min) and serotonin (5-HT; 10 nM-10 mM; 15 min) produced no changes
on TrkB phosphorylation in BDNF-responsive E18 rat cortical neurons (15DIV) as measured with phospho-TrkB ELISA. n = 4/group. Data is presented
as percentage of control 6 standard error of mean (SEM). *,0.05; two-way ANOVA with Newmann-Keuls post hoc test.
doi:10.1371/journal.pone.0020567.g005
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10 min, 37uC). Next the cells were triturated and suspended in a
medium containing 9.8 ml of Ca2+/Mg2+ free HBBS, 1 mM
sodium pyruvate, 10 mM HEPES and 10 ml DNAse I. The cells
were plated onto poly-L-lysine coated 12–24 well culture plates at
a cell density of 0.56106 ml21 (hippocampal) or 16106 ml21
(cortical). Cells were maintained in neurobasal medium (+2% B27
supplement, 1% penicillin/streptomycin, 1% glutamine and
25 mM glutamic acid; 5% CO2, +37uC) for 14 to 15 days in vitro
(DIV) before treatments. Parental MG87 and MG87-trkB
fibroblasts [48] were cultured in 12–48 well culture plates in
Dulbecco’s Modified Eagle’s Medium (DMEM) (+10% fetal calf
serum, 1% PEST, 1% L-Glutamine, 400 mg/ml G418; 5% CO2,
+37uC) and were stimulated under confluent conditions. The
following chemicals were used for the experiments: BDNF
(Peprotech), imipramine, amitriptyline, desipramine, chlorproma-
zine, phenelzine, clozapine, lithium (chloride salt). After the
treatments, the medium was discarded and the cells lyzed in NP++
buffer and processed for western blot analysis or for phospho-Trk
ELISA described below.
Phospho-Trk ELISA - An enzyme-linked immunosorbent assay
(ELISA) method was developed to easily measure the level of
phosphorylated Trk receptors from cultivated cells (Figure S4A).
Whereas in Trk expressing cells the assay readily detects BDNF- or
NGF-induced Trk phosphorylation, such induction is not detected
in cells not expressing Trk receptors (data not shown). Moreover,
BDNF-induced TrkB phosphorylation is lost if the cells are
pretreated with Trk kinase inhibitor k252a (data not shown).
Stimulation experiments were initiated by adding the drugs at
different concentrations onto confluent cell line cultures or with
primary neurons. After indicated incubation period at +37uC, the
medium was removed and the cells were lyzed with cold NP++
buffer (50–100 ml). In a set of experiments, these steps were carried
out by using Biomek FX workstation (Beckman Coulter) for the
liquid handling and incubation. Following.30 min incubation on
ice all material were transferred to pre-coated (sc-11-R, 1:500,
Santa Cruz Biotechnology; O/N at +4uC) and pre-blocked (2%
BSA/PBS-T; 2 h at RT) white 96-well OptiplateTM (PerkinElmer)
plates and 2–3% BSA/PBS-T (+2 mM Na3VO4) added ad 200 ml.
The plates were incubated O/N at +4uC and thereafter the wells
washed with PBS-T (46300 ml) and anti-phosphotyrosine anti-
body added to the wells (4G10, Upstate; 1:1000 in 5% NFDM/
PBS-T or in house biotinylated PY20, AbD Serotec, 1:1000 in 2%
BSA/PBS-T; both O/N at +4uC). Following sequential washes
and HRP-coupled tertiary antibody incubations (sheep anti-
mouse-HRP, 1:5000 in 5% NFDM/PBS-T or Streptavidin-
HRP, 1:10000 in 2% BSA/PBS-T; O/N at +4uC) 200 ml of
ECL substrate (Pierce) was added to the wells and luminescence
measured after 5 min with Varioskan Flash (Thermo Fisher
Scientific) plate reader.
Western blotting and sugar digestions – Lectin precipitation was
carried essentially as previously described [15] using triticum vulgaris
(Amersham or EY Laboratories). A set of lectin precipitated
samples were incubated with endoglycosidase-A (Endo-H) accord-
ing to manufacturer’s instructions (New England Biolabs). Proteins
were separated in a SDS-PAGE under reducing conditions and
blotted onto polyvinylidene difluoride (PVDF; Amersham) mem-
brane. After blocking (3% BSA/TBST, 1 h, RT), the membranes
were incubated with primary antibodies: anti-pY705/6 (own
1:500–1000, [49]; Cell Signaling 1:1000), anti-pY816 (1:5000, a
kind gift from Dr. Moses Chao, Skirball Institute, NY, USA), sc-
11-R (1:2000, Santa Cruz Biotechnology), anti-TrkB (1:2000, BD
Biosciences) or anti-BDNF (N-20/sc-546, Santa Cruz Biotechnol-
ogy). Moreover, the membranes were washed with TBST and
incubated with HRP-conjugated secondary antibody (1:10000 in
NFDM/TBST, 1 h, RT, Biorad). After subsequent washes, the
secondary antibodies were visualized using ECL kits (Amersham
Biosciences) followed by exposure to an X-ray film or Fuji LAS-
3000 camera (Tamro Medlabs, Finland) for ECL detection.
Data quantitation and statistical analysis - Immunoblots were
quantitated using NIH ImageJ 1.32. Statistical analyses were done
using two-sample two-tailed Student t-test or when appropriate
with one or two-way ANOVA followed with Newmann-Keuls post
hoc test. Statistically significant P-value was set to 0.05. Data are
presented as mean 6 standard error of mean and as percentage of
respective control.
Supporting Information
Figure S1 Diverse antidepressant drugs induce,105 kDa
protein phosphorylation in the mouse brain. A) Representa-
tive blot showing the time-response (30 min, 60 min, 120 min) of
fluoxetine-induced (20/30 mg/kg, i.p.) phosphorylation of TrkB
and ,105 kDa protein (Y816 in left; Y705/6 in right) in mouse
hippocampus. B) Representative blots showing antidepressant-
induced phosphorylation of ,105 kDa in mouse hippocampus C)
Representative blots showing imipramine-induced phosphory-
lation of ,105 kDa in mouse striatum, midbrain and whole
brain homogenate. Abbreviations: FLX= fluoxetine, SAL= saline;
CIT= citalopram; AMI= amitriptyline; CLO=clomipramine;
MOC=moclobemide; REB= reboxetine; MW=molecular
weight; TrkB.extr = antibody directed against the extracellular
portion of TrkB receptors.
(TIF)
Figure S2 Acute fluoxetine treatment did not regulate
BDNF protein levels or tPA (tissue plasminogen activa-
tor) activity. A) Representative blot showing mature-BDNF
specific band in western blot from brain homogenates and pro-
and mature-BDNF specific bands from respective control lanes as
detected with polyclonal BDNF antibody (N-20/sc-546; Santa
Cruz). Acute fluoxetine did not regulate mature-BDNF levels in
mouse hippocampus. n= 6/group. B) Representative zymography
showing caseinolysis at the level of recombinant tPA. Acute
fluoxetine did not regulate tPA activity levels in mouse
hippocampus. n= 6/group. Data is presented as percentage of
control 6 standard error of mean (SEM).
(TIF)
Figure S3 Blockade of adenosine-A2A receptor signaling
does not prevent antidepressant-induced TrkB activa-
tion. Acute imipramine treatment (30 mg/kg, i.p., 30 min; n = 6/
group) induces essentially similar changes on TrkB phosphoryla-
tion in vehicle and adenosine-A2A receptor antagonist
(ZM241358; 1 mg/kg, i.p., 30 min) pre-treated mice. A represen-
tative blot in left showing imipramine-induced phosphorylation of
TrkB and ,105 kDa protein in mouse brain. Data is presented as
percentage of control/saline 6 standard error of mean (SEM).
*,0.05; two-way ANOVA with Newmann-Keuls post hoc test.
(TIF)
Figure S4 Phospho-TrkB enzyme-linked immunosor-
bent assay (ELISA). A) Dose-response of BDNF (2, 8, 20 ng/
ml, 15 min) on TrkB phosphorylation in TrkB expressing fibroblasts
cultivated in 48-well plates. n= 4/group. B) Whereas BDNF
produces robust TrkB phosphorylation in TrkB expressing
fibroblasts cultivated in 24-well plates, all the tested drugs at
selected doses did not have any effect on TrkB phosphorylation
(compounds incubated for 15 min). n = 3/group. Data is presented
as percentage of control 6 standard error of mean (SEM).
Abbreviations: IMI= imipramine; PHE=phenelzine; FLX=
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fluoxetine; CLOZ=clozapine; Li = lithium chloride; CHLOR=
chlorpromazine.
(TIF)
Acknowledgments
The authors would like to thank the laboratory members of Professor. Eero
Castre´n, especially Outi Nikkila¨, Henri Autio, Ettore Tiraboschi and Juha
Knuuttila for excellent technical and academic assistance. Professor Jari
Yli-Kauhaluoma (University of Helsinki, Finland) is thanked for providing
the NaPP1 inhibitor, and Professor Moses Chao (Skirball Institute, NY,
USA) is thanked for providing phospho-TrkBY816 antibody.
Author Contributions
Conceived and designed the experiments: TR ADL PT K-PL MR EC.
Performed the experiments: TR LV HA ADL PT AS. Analyzed the data:
TR ADL. Wrote the paper: TR EC.
References
1. McAllister AK, Katz LC, Lo DC (1999) Neurotrophins and synaptic plasticity.
Annu Rev Neurosci 22: 295–318.
2. McAllister AK, Lo DC, Katz LC (1995) Neurotrophins regulate dendritic
growth in developing visual cortex. Neuron 15: 791–803.
3. Huang EJ, Reichardt LF (2001) Neurotrophins: Roles in neuronal development
and function. Annu Rev Neurosci 24: 677–736.
4. Poo MM (2001) Neurotrophins as synaptic modulators. Nat Rev Neurosci 2:
24–32.
5. Thoenen H (1995) Neurotrophins and neuronal plasticity. Science 270:
593–598.
6. Lee FS, Chao MV (2001) Activation of trk neurotrophin receptors in the absence
of neurotrophins. Proc Natl Acad Sci U S A 98: 3555–3560.
7. Rajagopal R, Chen ZY, Lee FS, Chao MV (2004) Transactivation of trk
neurotrophin receptors by G-protein-coupled receptor ligands occurs on
intracellular membranes. J Neurosci 24: 6650–6658.
8. Huang YZ, McNamara JO (2010) Mutual regulation of src family kinases and
the neurotrophin receptor TrkB. J Biol Chem 285: 8207–8217.
9. Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, et al. (2009) Amitriptyline
is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimer-
ization and has potent neurotrophic activity. Chem Biol 16: 644–656.
10. Pezet S, Malcangio M (2004) Brain-derived neurotrophic factor as a drug target
for CNS disorders. Expert Opin Ther Targets 8: 391–399.
11. Schindowski K, Belarbi K, Buee L (2008) Neurotrophic factors in Alzheimer’s
disease: Role of axonal transport. Genes Brain Behav 7: (Suppl 1) 43–56.
12. Rantama¨ki T, Castre´n E (2008) Targeting TrkB neurotrophin receptor to treat
depression. Expert Opin Ther Targets 12: 705–15.
13. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, et al. (2003)
Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs
and is required for antidepressant-induced behavioral effects. J Neurosci 2:
349–357.
14. Sairanen M, Lucas G, Ernfors P, Castre´n M, Castre´n E (2005) Brain-derived
neurotrophic factor and antidepressant drugs have different but coordinated
effects on neuronal turnover, proliferation, and survival in the adult dentate
gyrus. J Neurosci 25: 1089–1094.
15. Rantama¨ki T, Hendolin P, Kankaanpa¨a¨ A, Mijatovic J, Piepponen P, et al.
(2007) Pharmacologically diverse antidepressants rapidly activate brain-derived
neurotrophic factor receptor TrkB and induce phospholipase-cgamma signaling
pathways in mouse brain. Neuropsychopharmacology 32: 2152–2162.
16. Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB
mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug
treatments. J Neurosci 15: 7539–7547.
17. Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, et al. (2007)
Brain-derived neurotrophic factor conditional knockouts show gender differ-
ences in depression-related behaviors. Biol Psychiatry 61: 187–97.
18. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001) Increased
hippocampal BDNF immunoreactivity in subjects treated with antidepressant
medication. Biol Psychiatry 50: 260–265.
19. Sen S, Duman R, Sanacora G (2008) Serum brain-derived neurotrophic factor,
depression, and antidepressant medications: Meta-analyses and implications.
Biol Psychiatry 64: 527–532.
20. Wyneken U, Sandoval M, Sandoval S, Jorquera F, Gonzalez I, et al. (2006)
Clinically relevant doses of fluoxetine and reboxetine induce changes in the TrkB
content of central excitatory synapses. Neuropsychopharmacology 31: 2415–23.
21. Chen X, Ye H, Kuruvilla R, Ramanan N, Scangos KW, et al. (2005) A chemical-
genetic approach to studying neurotrophin signaling. Neuron 46: 13–21.
22. Koponen E, Voikar V, Riekki R, Saarelainen T, Rauramaa T, et al. (2004)
Transgenic mice overexpressing the full-length neurotrophin receptor trkB
exhibit increased activation of the trkB-PLCgamma pathway, reduced anxiety,
and facilitated learning. Mol Cell Neurosci 26: 166–181.
23. Koponen E, Lakso M, Castre´n E (2004) Overexpression of the full-length
neurotrophin receptor trkB regulates the expression of plasticity-related genes in
mouse brain. Brain Res Mol Brain Res 130: 81–94.
24. Watson FL, Porcionatto MA, Bhattacharyya A, Stiles CD, Segal RA (1999)
TrkA glycosylation regulates receptor localization and activity. J Neurobiol 39:
323–336.
25. Lee FS, Rajagopal R, Chao MV (2002) Distinctive features of trk neurotrophin
receptor transactivation by G protein-coupled receptors. Cytokine Growth
Factor Rev 13: 11–17.
26. Miranda C, Di Virgilio M, Selleri S, Zanotti G, Pagliardini S, et al. (2002) Novel
pathogenic mechanisms of congenital insensitivity to pain with anhidrosis genetic
disorder unveiled by functional analysis of neurotrophic tyrosine receptor kinase
type 1/nerve growth factor receptor mutations. J Biol Chem 277: 6455–6462.
27. Lu B, Pang PT, Woo NH (2005) The yin and yang of neurotrophin action. Nat
Rev Neurosci 6: 603–614.
28. Rios M, Fan G, Fekete C, Kelly J, Bates B, et al. (2001) Conditional deletion of
brain-derived neurotrophic factor in the postnatal brain leads to obesity and
hyperactivity. Mol Endocrinol 15: 1748–1757.
29. Wiese S, Jablonka S, Holtmann B, Orel N, Rajagopal R, et al. (2007) Adenosine
receptor A2A-R contributes to motoneuron survival by transactivating the
tyrosine kinase receptor TrkB. Proc Natl Acad Sci U S A 104: 17210–17215.
30. Sebastiao AM, Ribeiro JA (2009) Triggering neurotrophic factor actions through
adenosine A2A receptor activation: Implications for neuroprotection.
Br J Pharmacol 158: 15–22.
31. Phillis JW, Wu PH (1982) The effect of various centrally active drugs on
adenosine uptake by the central nervous system. Comp Biochem Physiol C 72:
179–187.
32. Pires VA, Pamplona FA, Pandolfo P, Fernandes D, Prediger RD, et al. (2009)
Adenosine receptor antagonists improve short-term object-recognition ability of
spontaneously hypertensive rats: A rodent model of attention-deficit hyperac-
tivity disorder. Behav Pharmacol 20: 134–145.
33. Lobato KR, Binfare RW, Budni J, Rosa AO, Santos AR, et al. (2008)
Involvement of the adenosine A1 and A2A receptors in the antidepressant-like
effect of zinc in the forced swimming test. Prog Neuropsychopharmacol Biol
Psychiatry 32: 994–999.
34. Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, et al. (2004)
Regional differences in extracellular dopamine and serotonin assessed by in vivo
microdialysis in mice lacking dopamine and/or serotonin transporters.
Neuropsychopharmacology 29: 1790–1799.
35. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related
mood disorders. Biol Psychiatry 59: 1116–27.
36. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM (1997) Antidepressant-like
effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav
56: 131–137.
37. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS (2002) Brain-
derived neurotrophic factor produces antidepressant effects in behavioral models
of depression. J Neurosci 22: 3251–3261.
38. Koponen E, Rantama¨ki T, Voikar V, Saarelainen T, Macdonald E, et al. (2005)
Enhanced BDNF signaling is associated with an antidepressant-like behavioral
response and changes in brain monoamines. Cell Mol Neurobiol 25: 973–980.
39. Saarelainen T, Vaittinen S, Castre´n E (2001) TrkB-receptor activation
contributes to the kainate-induced increase in BDNF mRNA synthesis. Cell
Mol Neurobiol 21: 429–435.
40. Martinowich K, Lu B (2008) Interaction between BDNF and serotonin: Role in
mood disorders. Neuropsychopharmacology 33: 73–83.
41. Mattson MP, Maudsley S, Martin B (2004) BDNF and 5-HT: A dynamic duo in
age-related neuronal plasticity and neurodegenerative disorders. Trends
Neurosci 27: 589–594.
42. Lucchelli A, Santagostino-Barbone MG, Barbieri A, Candura SM, Tonini M
(1995) The interaction of antidepressant drugs with central and peripheral
(enteric) 5-HT3 and 5-HT4 receptors. Br J Pharmacol 114: 1017–1025.
43. Raabe R, Gentile L (2008) Antidepressant interactions with the NMDA NR1-1b
subunit. J Biophys 2008: 474205.
44. Rammes G, Rupprecht R (2007) Modulation of ligand-gated ion channels by
antidepressants and antipsychotics. Mol Neurobiol 35: 160–174.
45. Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996) Interactions of selective
serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain.
Eur J Pharmacol 307: 117–119.
46. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, et al. (1998)
Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-
methylenedioxymethamphetamine (‘‘ecstasy’’) in serotonin transporter-deficient
mice. Mol Pharmacol 53: 649–655.
47. Murphy DL, Lesch KP (2008) Targeting the murine serotonin transporter:
Insights into human neurobiology. Nat Rev Neurosci 9: 85–96.
48. Vesa J, Kruttgen A, Shooter EM (2000) p75 reduces TrkB tyrosine
autophosphorylation in response to brain-derived neurotrophic factor and
neurotrophin 4/5. J Biol Chem 275: 24414–24420.
49. Rantama¨ki T, Knuuttila JE, Hokkanen ME, Castre´n E (2006) The effects of
acute and long-term lithium treatments on trkB neurotrophin receptor activation
in the mouse hippocampus and anterior cingulate cortex. Neuropharmacology
50: 421–427.
Antidepressants Transactivate TrkB Receptors
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20567
